
Africa, the cradle of the HIV pandemic, must be the cradle of the cure
They say history is written by the victors. But in the case of HIV, the story isn't over. Not by a long shot. And if we're honest — if we're truly listening — it is Africa that holds the pen for the next chapter.
Let's call it what it is: the HIV pandemic has Africa as its epicentre. More than 25 million people on the continent live with the virus. That's more than two thirds of the world's HIV-positive population. Here's the truth, raw and unfiltered: there will be no HIV cure without Africa.
Why does cure research in Africa matter? Because science divorced from relevance is science done wrong. The virus here is different — literally. Subtype C, dominant in Southern Africa, behaves in unique ways compared to subtype B, the strain most studied in Western labs. A cure crafted without considering this risks being ineffective.
But it's not just virology. It's people. Culture. History. It's the grandmother in rural Malawi still caring for five orphaned grandchildren. It's the young man in Soweto tired of hiding his status. It's the community health worker who's seen more funerals than birthdays.
Yet, scaling research in Africa is like climbing a muddy mountain in the rain. The challenges are real and they're brutal.
First, the money. Or the lack thereof. African research institutions are starved of resources. Laboratories are too few, too outdated or too dependent on external donors whose priorities shift with the wind. Promising trials stall, not for lack of will, but for lack of wi-fi or reagents. A potential cure is held hostage by broken centrifuges and expired funding cycles.
Second, the regulatory swamp. Clinical trials understandably need approval. But in Africa, the processes can be glacial. Ethics committees, often underfunded and overworked, are left to wade through complex protocols with limited support. Meanwhile, researchers — eager, bright, burning with passion — wait. And wait. Time bleeds. Momentum fades.
Then, there's trust. Or rather, the scars left by its absence. For decades, Africa has been the testing ground for drugs, devices and diagnostics, many of which never returned in the form of benefit. People remember. So when someone says, 'We're testing a cure,' people in Africa ask, for who and at what cost? Without deep, honest community engagement, even the best science will sit in sterile labs, untouched, unused.
Oh, and don't forget the brain drain. Bright African minds are too often lured abroad. Can you blame them? Better funding. Better infrastructure. More recognition. But the loss is ours. When the very people best positioned to solve Africa's problems have to solve someone else's, that's not just sad, it's sabotage.
So, what now? Roll over and wait for Western labs to save the day?
Absolutely not.
What's needed is a fundamental shift, a re-imagining of how global science is done. One that sees Africa not as a passive recipient of cure breakthroughs but as a co-creator. A leader. A standard-setter.
We need to fund African-led research and advocacy institutions such as the African HIV Cure Consortium (AHCC), not as side projects but as central nodes of global strategy. We need regulatory harmonisation across borders so that a trial approved in Kenya isn't buried in red tape in Nigeria. We need to invest not only in labs, but in people, in narratives of ownership and pride.
And, most critically, we must demand that cure research be ethical, inclusive and future-focused. No more parachute science. No more backroom deals. No more data extraction without shared benefit. Africa must be in the driver's seat, hands on the wheel, eyes on the road ahead.
A cure isn't just a medical milestone. It's a justice issue. To end HIV without ending inequality would be to miss the point entirely. If the cure becomes another tool of global exclusion — available in Boston before Bulawayo, or Paris before Pretoria — then we haven't cured anything. We've only perpetuated the disease of disparity.
Africa deserves better, it demands and needs to do better, because the people who've borne the brunt of this pandemic have also carried the torch of resilience, courage and hope.
Dr Albert Machinda is the co-principal investigator and head of secretariat for the Africa HIV Cure Consortium funded by the Gates Foundation and AIDSFonds.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

The Herald
8 hours ago
- The Herald
Drowning rates in SA go up while global figures drop, says Lifesaving SA
Drownings in South Africa are increasing, bucking the global trend where the rates are dropping, Lifesaving South Africa (LSA) warned in a statement to mark World Drowning Prevention Day on Friday. 'While global drowning deaths have dropped by 38% over the past two decades, South Africa's rates are rising,' the federation said, adding the World Health Organisation (WHO) estimated at least 2,700 drowning deaths a year, with children under five at the greatest risk. Africa has seen a 3% decline, while South Africa has struggled to deal with the threat. WHO statistics showed at least 1,600 drowning deaths a year in the country, but these figures did not include deaths from flooding disasters, LSA said. 'In South Africa the crisis is worsened by climate change and flooding disasters, such as those in the Eastern Cape in June, and preventable risks such as unsafe farm dams and canals, inadequate water and sanitation infrastructure and traditional baptism ceremonies at rivers and along coastline.'

TimesLIVE
12 hours ago
- TimesLIVE
US-funded contraceptives for poor nations to be burnt in France, sources say
US-funded contraceptives worth nearly $10m (R177.15m) are being sent to France from Belgium to be incinerated after Washington rejected offers from the UN and family planning organisations to buy or ship the supplies to poor nations, two sources told Reuters. A spokesperson for the US state department confirmed to Reuters on Wednesday that a decision had been taken to destroy the stock. The supplies have been stuck for months in a warehouse in Geel, a city in the Belgian province of Antwerp, after President Donald Trump's decision to freeze US foreign aid in January. They comprise contraceptive implants and pills as well as intrauterine devices to help prevent unwanted pregnancies, according to seven sources and a screengrab shared by an eighth source confirming the planned destruction. The US government will spend $167,000 (R2.95m) to incinerate the stocks at a facility in France that handles medical waste, the US state department confirmed. The spokesperson said a preliminary decision had been made to destroy certain products from terminated US Agency for International Development contracts (USAID). 'Only a limited number of commodities have been approved for disposal,' the spokesperson said via email, adding that no condoms or HIV medications would be destroyed. US legislators have introduced two bills this month to prevent the destruction of the supplies after Trump's decision to shut down USAID, but aid groups say the bills are unlikely to be passed in time to stop the incineration.


Mail & Guardian
a day ago
- Mail & Guardian
Poultry sector recovering, prices not expected to increase
South Africa's poultry sector is recovering from a devastating outbreak of bird flu and has capacity to meet local consumer demand. (Madelene Cronje) South Africa's The department of agriculture rolled out mass inoculations earlier this month to protect the industry from highly pathogenic In 2023, millions of birds had to be culled, hampering production and driving up poultry and egg prices. The inoculation campaign kicked off with the vaccination of 200 000 broiler breeders at poultry producer Astral. The birds represent 5% of the company's total breeding stock, the department said. Industry experts have welcomed the inoculation drive. 'We had two cases of HPAI in the country, but both were contained and did not spread with minimum losses in terms of production,' said Izaak Breitenbach, the chief executive of the South African Poultry Association. 'We still have an additional one million birds per week slaughter capacity. We currently slaughter about 21.5 million birds per week.' That number reflects normal production levels, which may rise slightly toward December because sales typically increase in the second half of the year. Breitenbach said the industry also has the capacity to exceed this demand if needed 'The industry can cover an increase in demand of about 10% with local production in the short term and probably more in the long term.' Agriculture economists said the success rate for the inoculations will depend on how well future outbreaks are contained. (Graphic: John McCann/M&G) 'There are great expectations that South Africa's recent efforts to vaccinate poultry against avian flu will lessen the likelihood of another devastating outbreak similar to the one that occurred in 2023. Particularly in light of the seasonal influenza outbreak, which usually starts in April and peaks in September each year,' said Thabile Nkunjana, of the National Agricultural Marketing Council. 'However, the initial vaccination is reportedly for at least 200 000 broilers, which is extremely small compared to the size of the industry as a whole. As a result, there is still a chance of an outbreak related to South African poultry production, as well as a current risk of disruptions in the poultry supply, which frequently results in prices that have a negative impact on consumers The layer side of the poultry industry, which raises chickens specifically for egg production, is still producing at lower levels comparable to those before the 2023 outbreak, Nkunjana noted. 'If an outbreak were to occur, the industry would likely experience the same level of pressure as it did in 2023, and egg prices would probably rise once more,' he said. Experts warned that the cost of bird feed could hamper poultry production. Prices have increased on the back of climate conditions as well as international supply. 'Initially feed costs rose when world prices increased sharply in the aftermath of the pandemic and associated supply chain challenges, challenging weather in some key production regions and Russia's invasion of Ukraine,' said Tracy Davids, the executive director for commodity markets and foresight at the Bureau for Food and Agricultural Policy. 'When world prices came down, South African prices stayed higher due to the summer drought of 2024. So, feed costs have increased much more than meat prices over the past five years, making life difficult for all livestock producers, but particularly poultry that use feed very intensively. It's the biggest cost component in the sector.' With feed prices declining and the partial lifting of the ban on Brazilian chicken imports earlier this month, the prospects for the sector are looking positive, Davids added. The ban was implemented after Brazil also reported disease outbreaks, but was lifted to support South African consumers' food security, alleviate cost pressures, and help stabilise the supply chain, said Nkunjana.